Advair Powder
Product Images NDC 50090-0730

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair (NDC 50090-0730). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Advair Diskus Spl Graphic 01)

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 02)

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 03)

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 04)

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 05)

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 06)

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus Spl Graphic 06)
This appears to be a medical document or chart displaying data related to the efficacy of the medication Advair Diskus compared to a placebo and Sameterol in the treatment of respiratory conditions. The values represent FEV (Forced Expiratory Volume) measured in milliliters, taken at different time intervals (week) during the treatment. The data suggests that patients taking Advair Diskus showed an improvement in lung function compared to those taking a placebo or Sameterol.*
FDA Label Image

Figure 5 (Advair Diskus Spl Graphic 07)

Figure 5 (Advair Diskus Spl Graphic 07)
This appears to be a table providing product information for a medicine called ADVAIR DISKUS 25050, alongside two other products named Futcasions ropinals 250 and Placebo. It lists their baseline FEV (forced expiratory volume) values and specific doses. There is also a section with numerical values on the right which is unclear without further context.*
FDA Label Image

Figure 6 (Advair Diskus Spl Graphic 08)

Figure 6 (Advair Diskus Spl Graphic 08)
This is a list of different parts or components of a product, possibly related to some kind of device or tool. There is an outer case, a mouthpiece, and a thumb grip. No information is provided on what kind of product or tool these parts belong to.*
FDA Label Image

Ifu Figure A (Advair Diskus Spl Graphic 09)

FDA Label Image

Ifu Figure B (Advair Diskus Spl Graphic 10)

FDA Label Image

Ifu Figure C (Advair Diskus Spl Graphic 11)

FDA Label Image

Ifu Figure D (Advair Diskus Spl Graphic 12)

FDA Label Image

Ifu Figure E (Advair Diskus Spl Graphic 13)

FDA Label Image

Ifu Figure F (Advair Diskus Spl Graphic 14)

FDA Label Image

Ifu Figure G (Advair Diskus Spl Graphic 15)

FDA Label Image

Label Image (Lbl500900731)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.